H.U. Group Holdings,Inc. FY2026 FY Earnings Report

クイックビュー

Executive Summary

For the fiscal year ended March 2026, Revenue was ¥2,473.6B (YoY +¥43.4B +1.8%), Operating Income was ¥47.8B (YoY +¥21.4B +81.0%), Ordinary Income was ¥28.3B (YoY -¥19.1B -40.2%), and Net Income attributable to owners of the parent was ¥68.2B (YoY +¥40.6B +147.1%). Operating performance achieved a significant recovery, improving the operating margin to 1.93% (prior year 1.09%), but Ordinary Income declined due to a ¥9.0B equity-method loss. Net Income was supported by ¥68.4B of non-recurring gains, including ¥22.9B gain on sale of fixed assets and ¥39.3B gain on sale of subsidiary shares. Gross margin improved to 28.9% from 27.6% a year earlier (+1.3pt), driven by sustained high margins in the IVD segment and company-wide expense compression.

業績変動要因

[Revenue] Revenue was ¥2,473.6B, a modest increase of +1.8% YoY. By segment, Clinical Lab Testing (testing & related services) was ¥1,576.1B (+2.7%), In Vitro Diagnostics (clinical test reagents) was ¥649.9B (±0.0%), and Sterilization And Related Services (sterilization & surgical-related) was ¥294.5B (-0.4%). The slight increase in testing & related services drove the overall result. By region: Japan ¥2,081.5B (domestic 85.9%), U.S. ¥121.9B, Europe ¥178.2B, Other ¥92.0B. Cost of sales was ¥1,759.8B, representing a cost of sales ratio of 71.1% and a gross margin of 28.9% (up 1.3pt YoY), confirming effects of price improvement and cost control.

[Profitability] Operating Income recovered substantially to ¥47.8B (+81.0% YoY). SG&A was ¥666.0B (SG&A ratio 26.9%), up +3.2% YoY, but increased gross profit and restraint of company-wide expenses (pre-segment adjustment equivalent ¥186.6B → ¥185.6B) improved the operating margin to 1.93%. R&D expense was ¥111.7B (4.5% of sales), strengthening the IVD product pipeline. Ordinary Income was ¥28.3B (-40.2%), burdened by a ¥9.0B equity-method loss and ¥6.9B interest expense; non-operating items net worsened by ¥19.4B. Profit before tax was ¥85.8B, and non-recurring items of ¥68.4B (gain on sale of fixed assets ¥22.9B, gain on sale of subsidiary shares ¥39.3B, etc.) and extraordinary losses of ¥11.0B (impairment of fixed assets ¥4.0B, loss on liquidation of subsidiaries ¥0.92B, etc.) lifted the bottom line. Net income attributable to owners of the parent was ¥68.2B (+147.1%), with a net margin of 2.76%, though about 41% of profit was due to non-recurring items. In conclusion, the company achieved revenue and profit growth at the operating level, while Ordinary Income decreased and non-operating/extraordinary items had a large impact.

セグメント別分析

By segment, Clinical Lab Testing (testing & related services) reported Revenue ¥1,576.1B and Operating Income ¥0.31B (prior year -¥46.4B), achieving a substantial improvement to an effectively flat margin of 0.0%. In Vitro Diagnostics (clinical test reagents) reported Revenue ¥649.9B and Operating Income ¥90.5B (prior year ¥113.5B), maintaining a high margin of 13.9% but declining -20.2% YoY. Sterilization And Related Services (sterilization & surgical-related) reported Revenue ¥294.5B and Operating Income ¥17.6B (prior year ¥17.8B), maintaining a margin of 6.0%. IVD accounts for approximately 80% of Operating Income and is the core earnings pillar, while testing & related services faces structural margin challenges. Company-wide expenses are approximately ¥186B equivalent, compressing consolidated operating margin.

主要財務指標

[Profitability] Operating margin 1.93% (prior year 1.09%), Net margin 2.76% (prior year 1.14%) both improved. ROE 5.7% (on an Equity Ratio of 51.4%) indicates modest capital efficiency. EBITDA was ¥259.2B (Operating Income ¥47.8B + Depreciation ¥211.4B), giving an EBITDA margin of 10.5%. Gross margin 28.9% (YoY +1.3pt) and SG&A ratio 26.9% indicate limited operating leverage. [Cash Quality] Operating Cash Flow / Net Income ratio was 3.16x, indicating high quality; OCF/EBITDA ratio was 0.83x, near standard. Receivables turnover period 69 days, inventory turnover period 143 days, indicating somewhat heavy inventory (work-in-process ¥6.97B accounts for 40.5% of total inventory). [Investment Efficiency] ROIC 3.4% may be below the cost of capital. CapEx/Depreciation ratio 0.11x is extremely low, signaling underinvestment for future competitiveness. Capital expenditure was ¥23.6B, about one-tenth of depreciation ¥211.4B. R&D was ¥111.7B (4.5% of sales) to advance IVD development. [Financial Soundness] Equity Ratio 51.4%, Debt/Equity 27.6%, Debt/EBITDA 0.74x, Interest Coverage 37.8x indicate strong financial resilience. Current ratio 172.1%, Quick ratio 162.8% show sufficient liquidity. Short-term debt ratio 52.2% is somewhat high, posing potential maturity mismatch risk, but Cash/Short-term debt ratio 4.81x provides ample liquidity buffer. Interest-bearing debt totaled approximately ¥365B (long-term borrowings ¥91.5B, short-term borrowings ¥100B, total corporate bonds ¥311B), with long-term borrowings down -52% YoY.

キャッシュフロー分析

Operating Cash Flow was ¥215.7B, 3.16x Net Income, and net operating cash inflow was ¥240.7B, a healthy level; however, working capital increases (Receivables -¥3.0B, Inventories -¥16.6B, Accounts payable +¥9.3B for a net approx. -¥10B) and corporate tax payments ¥23.5B were absorption factors. Investing Cash Flow was +¥113.4B, driven by one-off inflows: sale of fixed assets ¥44.8B, proceeds from sale of subsidiary shares ¥49.5B, and loan recoveries ¥60.7B; CapEx was only -¥23.6B. Free Cash Flow was ¥329.0B, ample, but the sustainability of investing CF contributions warrants attention. Financing Cash Flow was -¥263.9B, including repayment of long-term borrowings -¥100.5B, redemption of corporate bonds -¥100B, dividend payments -¥71.5B, share buybacks -¥50.0B, and lease repayments -¥44.8B, reflecting debt reduction and shareholder returns. Cash and cash equivalents at period end were ¥481.0B, up ¥72.2B from ¥408.8B at period start; foreign exchange effects ¥7.1B also contributed.

収益の質

There is a large gap between Ordinary Income ¥28.3B and Net Income ¥68.2B, with non-recurring gains of ¥68.4B (gain on sale of fixed assets ¥22.9B, gain on sale of subsidiary shares ¥39.3B, step-acquisition gain ¥1.5B, etc.) accounting for roughly 41% of profit. Non-operating income was ¥8.6B, mainly interest income ¥4.0B and dividends ¥0.7B; non-operating expense was ¥28.0B, led by equity-method loss ¥9.0B and interest expense ¥6.9B. Extraordinary losses were ¥11.0B, mainly impairment of fixed assets ¥4.0B and loss on liquidation of subsidiaries ¥0.92B. Comprehensive income was ¥122.7B, ¥54.5B higher than Net Income, mainly due to foreign currency translation adjustments ¥49.3B and remeasurements of defined benefit plans ¥6.6B. Operating Cash Flow at 3.16x Net Income indicates strong cash conversion and high accrual quality. Normalized profit excluding one-offs is estimated at approximately ¥30–40B, and next fiscal year should be monitored for a reversal of asset sale gains.

業績予想・ガイダンス

The company’s full-year forecast for the fiscal year ending March 2027 is: Revenue ¥2,560B (YoY +3.5%), Operating Income ¥90B (YoY +88.3%), Ordinary Income ¥80B (YoY +182.3%), Net Income attributable to owners of the parent ¥50B (YoY -26.7%), and EPS ¥90.11. The plan assumes raising operating margin to approximately 3.5% through margin improvement in testing & related services, product and regional mix improvements in IVD, and continued company-wide expense optimization. Ordinary Income assumes improvement in equity-method results and reduced interest burden; Net Income assumes a rebound from the prior year’s large non-recurring gains. Dividend forecast is annual ¥62 with an expected payout ratio of about 70%, normalizing to a sustainable level. Achievement of the full-year forecast hinges on first-half progress and realization of operating leverage.

株主還元

Annual dividend was ¥125 (¥62 at Q2-end, ¥63 year-end), total dividend payments ¥71.5B, with a payout ratio of 105.3% exceeding earnings; however, Free Cash Flow ¥329B covers this 4.6x, indicating high cash sustainability. Share buybacks of ¥50.0B were executed, making total return ¥121.5B. Total return ratio coverage by FCF is about 2.7x, which is healthy. Next fiscal year’s forecast dividend is annual ¥62, implying a payout ratio of about 70% on forecast Net Income ¥50B, indicating normalization. Medium-term continuation of returns depends on sustained operating margin improvement and maintenance of FCF generation after re-accelerated investment.

リスク要因

1. Segment concentration & structural risk: Clinical Lab Testing accounts for 62.5% of Revenue but has an effectively zero operating margin and is vulnerable to fee schedule revisions and structural changes in testing demand (post-COVID) that pressure prices/volumes. IVD, which accounts for 80% of Operating Income, is on a -20.2% YoY decline; delays in new product development/approval could slow growth of this high-margin business. Company-wide expenses of about ¥186B equivalent continue to compress consolidated operating margins.

2. Financial structure & liquidity risk: Short-term debt ratio 52.2% entails refinancing and maturity mismatch risks; liquidity management is needed to address concentration of redemptions including total corporate bonds ¥311B (including ¥50B maturing within one year) and short-term borrowings ¥100B. Cash/Short-term debt ratio 4.81x provides practical resilience, but underinvestment (CapEx/Depreciation 0.11x) presents a latent risk of declining competitiveness. Carrying amount of tangible fixed assets is ¥654B, limiting impairment risk, but goodwill ¥86.8B and intangible assets ¥397B (total ¥484B, 18.1% of total assets) require ongoing impairment monitoring.

3. Working capital & earnings volatility risk: Receivables collection period 69 days and inventory turnover period 143 days cause significant cash tie-up, with work-in-process ratio 40.5% indicating inventory stagnation/quality/impairment risks. Continued or expanded equity-method losses ¥9.0B, volatility from reversal of gains on asset sales, and R&D investment ¥111.7B not realizing returns are earnings volatility factors. Supply-chain constraints or raw material cost increases that push up cost of sales also require ongoing attention.

業種ベンチマーク（参考・当社調べ）

Profitability & Return

Both operating margin and net margin are below the industry median, indicating relatively low profitability within the sector.

Growth & Capital Efficiency

Revenue growth rate is well below the industry median, showing the company lags peers in growth.

※Source: Company compilation

決算上の注目ポイント

1. The key point is whether the recovery trend in operating margin is sustainable. This fiscal year achieved operating margin 1.93% via gross margin +1.3pt and company-wide expense restraint, but reaching the company plan of about 3.5% requires margin improvement in testing & related services (currently 0.0%) and reversal of IVD’s profit decline. Continued compression of the SG&A ratio from 26.9% and improved R&D investment efficiency will determine sustainability of profit growth. Structurally, high dependence on IVD leaves testing & related services’ profit transformation a medium-term challenge.

2. Net Income was supported by non-recurring gains ¥68.4B, with roughly 41% of profit attributable to one-off items. Next year a reversal of asset sale gains is expected; therefore, autonomous improvement in operating margin and elimination of negative equity-method results are prerequisites for substantive profit growth. Cash generation (OCF/Net Income 3.16x, FCF ¥329B) is strong and financial capacity (Debt/EBITDA 0.74x) is ample, but underinvestment (CapEx/Depreciation 0.11x) signals risk to maintaining competitiveness. The payout ratio 105% reflects one-off profit upside and normalization to about 70% next year is reasonable. In the short term, stable dividends supported by liquidity are expected, but medium-to-long-term continuity of returns depends on sustained operating margin improvement and FCF generation after investment re-acceleration.

---

This report is an earnings analysis document automatically generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by our firm based on public financial statements. Investment decisions are your responsibility; consult professionals as needed before making investment decisions.

---End of Report---